RELX Group Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
RELX Group Bundle
See the Bigger Picture
Quick glance: RELX Group’s BCG Matrix snapshot shows where its businesses likely sit—market leaders, cash generators, or areas needing a rethink. Want the full picture? Purchase the complete BCG Matrix for quadrant-by-quadrant placement, data-backed recommendations and a ready-to-use Word report plus an Excel summary to guide investment and product decisions. Get instant strategic clarity and save hours of work—buy now.
Stars
LexisNexis Risk — Fraud & ID
High-growth demand for digital identity, fraud prevention and KYC—digital identity market CAGR ~14.8% (2024–2030)—keeps LexisNexis Risk running hot. RELX holds a leading position with deep data assets and mission-critical workflows across insurance, financial services and government. It soaks up investment in data, models and integrations but benefits from scale economics. Continue backing it to entrench share and position it for Cash Cow status.
Insurance Analytics & Scores
Usage-based underwriting, claims analytics and risk scores are scaling rapidly as insurers modernize; RELX reported double-digit growth in its risk analytics cohort in 2024, driven by telematics and IoT data ingestion. Strong data moats and embedded workflows give RELX a leading position versus peers. High growth requires cash for new data sources and model upgrades, with continued investment expected to harden the moat and widen share.
STM Analytics & Discovery
STM Analytics & Discovery (Scopus/SciVal-class) embeds discovery and analytics into researcher decisions; Scopus indexes over 88 million records and SciVal is used by more than 3,500 institutions, keeping RELX central to university and funder workflows. The market for research analytics continues expanding as universities and funders adopt analytics at core of workflows. RELX’s share is strong; capex is focused on platform upgrades and AI features, and holding share should let it mature into a Cash Cow.
Clinical Decision Tools
Clinical decision tools sit in RELX Group’s Stars quadrant as hospital and point-of-care CDS adoption accelerated in 2024, with the global CDS market estimated at about USD 2.1bn and ~11% CAGR; depth of Elsevier content plus embedded decision support creates a defensible clinical wedge. Integrations are capital-intensive, data quality drives outcomes and reimbursement, and locking clinician workflows via multi-year contracts is critical to capture brisk growth.
- Market 2024: USD 2.1bn (est)
- Projected CAGR: ~11%
- Moat: content + decision support
- Risk: high integration costs, data quality
- Strategy: invest to secure workflows & long-term contracts
Compliance & Financial Crime
Compliance & Financial Crime is a Stars segment in 2024 as rising global regulatory pressure increases demand for screening and monitoring solutions. RELX’s unmatched data breadth and high match accuracy create strong competitive moats. Rapid growth requires substantial cash to expand coverage and partnerships. Continued investment is warranted—this is a platform play with sticky renewals.
- Regulatory tailwinds 2024: stronger global AML/KYC demand
- Competitive strength: proprietary data + high match accuracy
- Capital use: heavy reinvestment for coverage & partnerships
- Business model: platform with high renewal stickiness
Risk double-digit; STM 88M; CDS 2.1bn11%
Stars: LexisNexis Risk, Compliance & Financial Crime, STM Analytics and Clinical Decision Support showing 2024 CAGR/outlook strength (risk analytics double-digit growth in 2024; Scopus 88M records; CDS market ~USD 2.1bn, ~11% CAGR). Strong data moats, high renewal stickiness; require heavy reinvestment to convert to Cash Cows.
| Segment | 2024 growth | Market 2024 | Moat |
|---|---|---|---|
| Risk & KYC | double-digit | — | proprietary data |
| STM/Scopus | mid-single-dig | 88M records | embedded workflows |
| CDS | ~11% CAGR | USD 2.1bn | content + integration |
What is included in the product
Detailed Word Document
BCG review of RELX units—maps Stars, Cash Cows, Question Marks and Dogs with actionable invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page RELX BCG Matrix placing each business unit in a quadrant—clean, export-ready for C-level review and PowerPoint drag-and-drop.
Cash Cows
ScienceDirect Subscriptions
ScienceDirect subscriptions form RELX/Elsevier’s flagship STM cash cow, hosting over 2,800 journals and 18+ million research items with entrenched institutional multi‑year deals. Market growth is modest (low single‑digit CAGR) while Elsevier’s high margins and low incremental sales costs sustain strong free cash flow. Continue milking efficiently and reinvest surgically in UX and interoperability to protect share.
Lexis Legal Research
Lexis Legal Research sits as a cash cow within RELX, embedding core legal guidance into firm workflows and supporting RELX Legal 2024 revenue of about £3.3bn within group revenue near £9.6bn. Mature markets, premium pricing and sub-5% churn drive steady cash; upsell to analytics raises ARPU without heavy promo. Maintain product quality and harvest predictable margins.
Elsevier Core Journals
Elsevier Core Journals comprise an established portfolio of over 2,500 peer‑reviewed titles (2024) with strong brand equity and citation gravity that sustain pricing power. Volume growth is modest, yet unit economics remain highly attractive. Scaled production and distribution drive high cash conversion, enabling RELX to recycle proceeds into next‑gen analytics and AI investments.
RX Flagship Events
RX Flagship Events are large global shows with a loyal exhibitor and attendee base, operating around 500 events in 40+ countries; growth is steady rather than explosive, yielding reliable cashflows while operations are highly tuned and marketing intensity remains moderate.
- Scale: 500+ events, 40+ countries
- Profile: loyal exhibitors/attendees
- Growth: steady, reliable yields
- Focus: pricing and operational optimization
Legal Practical Guidance
Legal Practical Guidance is a sticky cash cow with practice tools and precedents driving renewal rates around 90% in 2024, supporting efficient cross‑sell into mature law‑firm and corporate accounts; ongoing content refreshes keep value high without heavy capex, producing steady operating cash that funds RELX higher‑beta investments.
- renewal_rate: ~90% (2024)
- market_maturity: high, efficient cross‑sell
- capex_intensity: low (content refresh)
- role: reliable cash contributor for growth bets
Journals, legal renewals and 500+ events: high margins and steady cash in 2024
ScienceDirect, Lexis, Elsevier core journals, RX events and Legal Practical Guidance were RELX cash cows in 2024, delivering high margins and predictable free cash flow; Lexis Legal contributed ~£3.3bn to group revenue ~£9.6bn, Elsevier journals (≈2,500 titles) and ScienceDirect (≈2,800 journals, 18m+ items) drove strong ARPU, RX ran 500+ events, Legal renewals ≈90%.
| Business | 2024 metric | Margin/renewal | Role |
|---|---|---|---|
| ScienceDirect | 2,800 journals; 18m+ items | High | Core cash |
| Lexis | £3.3bn revenue | High | Stable cash |
| Elsevier journals | ≈2,500 titles | High | Pricing power |
| RX Events | 500+ events, 40+ countries | Moderate | Reliable cash |
| Legal Practical Guidance | Renewal ≈90% | High | Sticky cash |
Preview = Final Product
RELX Group BCG Matrix
The RELX Group BCG Matrix you're previewing here is the exact file you'll receive after purchase. No watermarks, no placeholders—just a fully formatted, analysis-ready report tailored to RELX's portfolio. It’s crafted for immediate use in strategy sessions, investor decks, or internal planning. Buy once, download instantly, and start presenting or editing right away.
Dogs
Legacy Print‑Only Titles
Legacy print‑only titles suffer declining demand, rising unit costs and limited differentiation—print now represents under 5% of RELX segment revenues in 2024, making them cash neutral at best and often a distraction from higher-margin digital products. With digital alternatives delivering scale, faster analytics and better margins, turnaround is difficult and costly. Prune aggressively and redeploy capital and talent into digital platforms and data services to maximize ROI.
CD/DVD Reference Products
CD/DVD reference products are an obsolete form factor with near-zero growth and minimal maintenance overhead; customers now expect cloud and API delivery instead. Revenue only trickles and primarily ties up support resources, making it a low-return Dog in RELX’s BCG matrix. Recommend sunsetting with clear migration paths to hosted APIs and data subscriptions to preserve client continuity and reduce support cost.
Small Regional Trade Shows
Small regional trade shows are Dogs: fragmented local audiences and sponsor fatigue lower ROI, while local competition and constrained corporate travel budgets cap growth. Operational complexity and overheads frequently outweigh modest returns, squeezing margins and allocation efficiency. Consolidate or divest these events to redeploy resources into scalable, high-growth franchises.
On‑Prem Legal Software Modules
On‑Prem Legal Software Modules sit in Dogs: customers are migrating to SaaS, upgrade cycles stall, support costs linger and margins compress; little competitive edge remains. IDC 2024 notes cloud deployments exceeded on‑prem in many enterprise software segments, forcing RELX to migrate or retire modules to cut the tail.
- Migrate: reduce support tail, capture SaaS ARR
- Retire: cut legacy OPEX and redeploy capital
- Measure: track maintenance spend vs ARR recovery
Low‑Margin Ad Directories
Low‑margin ad directories face platform competition and commoditization, eroding pricing power and user differentiation. Monetization is weak and volatile, with classifieds often showing single‑digit EBITDA contribution and pronounced quarterly revenue swings in 2024. Strategic value to RELX is limited; exit or fold listings into higher‑value information services and analytics.
- Competition: platform commoditization
- Monetization: weak, volatile in 2024
- Strategic value: limited
- Action: exit or integrate into premium products
Sunset low-growth print, CDs & shows; shift capital to high-growth data platforms
Legacy print under 5% of RELX segment revenue in 2024, CD/DVD revenues near zero, small regional shows and on‑prem modules show declining demand and thin margins; ad directories deliver single‑digit EBITDA in 2024. These Dogs tie up support/OPEX and cap investment in digital growth. Sunset, consolidate or migrate to SaaS/APIs and reallocate capital to high‑growth data platforms.
| Category | 2024 Rev share | 2024 EBITDA | Action |
|---|---|---|---|
| <5% | Neutral/low | Prune/migrate | |
| CD/DVD | ~0% | Negligible | Retire |
| Regional shows | Low | Negative/low | Consolidate/divest |
| On‑prem modules | Declining | Compressed | Migrate to SaaS |
| Ad directories | Low | Single‑digit EBITDA | Exit/integrate |
Question Marks
GenAI Research Assistants
GenAI Research Assistants are a rapidly growing but still contested question mark for RELX: market demand is high yet share remains fluid, and the opportunity scales only if tightly integrated with RELX’s vetted content and citation networks.
Realizing value requires heavy investment in proprietary models, robust guardrails, and UX tailored to legal, scientific, and regulatory workflows. Commit and differentiate on trust and explainability—or pivot fast if adoption and ROI don’t materialize.
AI‑Native Legal Drafting
AI‑native legal drafting is a Question Mark: law firms show strong demand but the space is crowded with startups and Big Tech entrants. RELX can leverage superior data quality and unmatched precedent coverage from LexisNexis to differentiate. However, cost to win is significant — GPU compute, human evaluation, and enterprise integrations drive CAPEX and operating expense. Move fast to scale in core practices or retrench if adoption and commercial traction lag.
ESG & Supply‑Chain Risk Analytics
Regulatory tailwinds are strong—EU CSRD expanded reporting to about 50,000 companies from 2024—yet standards and metrics are still settling and competition is noisy. RELX can differentiate by combining entity graphs with its news and legal datasets to detect supplier risk and litigation signals. Revenue is early and leadership in this niche remains uncertain, so invest selectively where compliance complexity is highest and buyer budgets are established.
Healthcare Real‑World Evidence
Question Marks: Healthcare Real‑World Evidence sits in a high-growth but uncertain BCG quadrant as pharma and payers increasingly demand outcomes data, while data rights and interoperability remain fragmented; 2024 industry reports show RWE adoption accelerating but commercial models still immature. Upfront costs and consortium partnerships are capital‑intensive; RELX can scale by testing niches with clear ROI and improving coverage and curation.
- Market: accelerating 2024 RWE demand
- Barrier: messy data rights & interoperability
- Cost: high upfront/platform partnerships
- Playbook: test, learn, scale niches with demonstrable ROI
SMB Risk & Credit in Emerging Markets
SMB risk and credit in emerging markets offer a large addressable opportunity—SMEs make up about 90% of businesses and 50% of employment globally, while the IFC estimated a developing-country SME financing gap of roughly 5.2 trillion USD. Current RELX penetration is low; data scarcity and localization add friction, but assembling reliable localized signals could create a durable analytics moat. Pilot in targeted countries before scaling.
- IFC_gap_5.2T
- SME_90%_biz_50%_jobs
- Low_penetration_Data_frictions
- Build_signals_for_moat
- Pilot_targeted_countries
GenAI, CSRD, RWE & SME risk: 50k firms, 5.2T gap
RELX Question Marks (GenAI, AI legal drafting, CSRD/regulatory analytics, RWE, emerging‑market SMB risk) show high market growth but uncertain share; 2024 signals: EU CSRD ~50,000 firms, IFC SME finance gap ~5.2T, RWE adoption rising. Winning needs heavy capex, data rights work, and narrow go‑to‑market bets; pivot if ROI lags.
| Theme | 2024 signal | Implication |
|---|---|---|
| GenAI | fast demand | large invest |
| CSRD | 50,000 firms | compliance sell‑in |
| SME | 5.2T gap | pilot markets |